A research letter published in Experimental Dermatology written by Chang-Yu Hsieh from the Department of Dermatology, National Taiwan University Hospital, Taipei City, Taiwan, entitled,.
DGAP-News: Immunic, Inc. / Key word(s): Study Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935 27.10.2021 / 12:30 The issuer is solely
The 52-week data from two pivotal trials with deucravacitinib, a first-in-class inhibitor of tyrosine kinase 2 (TYK2), demonstrated durable control of moderate-to-severe plaque psoriasis.